Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free LGND Stock Alerts

Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume

Ligand Pharmaceuticals logo
$302.92 +8.93 (+3.04%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Ligand Pharmaceuticals Short Interest Overview

As of June 30, 2026, Ligand Pharmaceuticals (LGND) had a short interest of 2.12 million shares sold short, representing 11.38% of the public float. This marks a 25.56% increase in short interest since the prior report. The short interest ratio (days to cover) is 2.6, meaning it would take 2.6 days of the average trading volume of 277,931 shares to cover all short positions.

Current Short Interest
2,121,617 shares
Previous Short Interest
1,689,714 shares
Change Vs. Previous Month
25.56%
Dollar Volume Sold Short
$670.62 million
Short Interest Ratio
2.6 Days to Cover
Last Record Date
June 30, 2026
Outstanding Shares
20,040,000 shares
Short Percent of Float
11.38%
Today's Trading Volume
71,278 shares
Average Trading Volume
277,931 shares
Today's Volume Vs. Average
26%
Short Selling Ligand Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

LGND Short Interest Over Time

LGND Days to Cover Over Time

LGND Percentage of Float Shorted Over Time

Ligand Pharmaceuticals Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/20262,121,617 shares $670.62 million +25.6%11.4%2.6 $316.09
6/15/20261,689,714 shares $427.92 million +3.1%9.1%8.33 $253.25
5/29/20261,638,411 shares $380.05 million +8.9%8.8%8.18 $231.96
5/15/20261,505,179 shares $320.92 million +3.4%8.1%6.67 $213.21
4/30/20261,455,087 shares $333.87 million +3.4%7.8%7.97 $229.45
4/15/20261,406,701 shares $316.63 million -5.9%7.5%5.26 $225.09
3/31/20261,495,607 shares $298.60 million +2.5%8.1%6.45 $199.65
3/13/20261,458,857 shares $296.02 million +5.9%7.9%5.76 $202.91
2/27/20261,378,177 shares $273.31 million +0.5%7.4%9.02 $198.31
2/13/20261,371,498 shares $252.12 million +6.9%7.4%6.93 $183.83
1/30/20261,283,046 shares $246.47 million +1.2%7.0%6.49 $192.10
1/15/20261,267,548 shares $248.54 million +1.7%6.9%4.55 $196.08
12/31/20251,246,230 shares $235.62 million +13.7%6.8%6.81 $189.07
12/15/20251,095,980 shares $211.39 million -1.2%6.0%4.77 $192.88
11/28/20251,108,765 shares $225.24 million +5.6%6.1%4.81 $203.15
11/14/20251,050,284 shares $210.96 million -5.2%5.8%4.24 $200.86
10/31/20251,107,928 shares $211.96 million -6.2%6.1%7.24 $191.31
10/15/20251,180,000 shares $216.29 million -1.7%6.5%5.4 $183.30
9/30/20251,200,000 shares $212.57 million +7.1%N/A5 $177.14
9/15/20251,120,000 shares $185.37 million -3.5%N/A4.7 $165.51
8/31/20251,160,000 shares $187.58 million -2.5%6.4%5.5 $161.71
8/15/20251,190,000 shares $179.79 million +29.9%N/A5.8 $151.08
7/31/2025915,900 shares $120.51 million -25.5%5.1%5.4 $131.58
7/15/20251,230,000 shares $152.89 million +3.4%N/A8.7 $124.30
6/30/20251,190,000 shares $135.28 million +3.5%6.6%9.7 $113.68
6/15/20251,150,000 shares $129.38 million -6.5%6.4%9.7 $112.50
5/31/20251,230,000 shares $126.90 million +12.8%6.9%10.2 $103.17
5/15/20251,090,000 shares $112.78 million -10.7%6.1%8.9 $103.47
4/30/20251,220,000 shares $134.03 million +7.0%N/A10.2 $109.86
4/15/20251,140,000 shares $121.75 million +12.9%6.4%10.1 $106.80
3/31/20251,010,000 shares $106.19 million +5.8%5.7%9 $105.14
3/15/2025955,100 shares $101.42 million +22.4%5.4%8.3 $106.19
2/28/2025780,100 shares $95.35 million -7.7%4.4%7.1 $122.23
2/15/2025845,000 shares $101.40 million -11.2%4.8%8 $120.00
1/31/2025951,500 shares $110.90 million +4.4%N/A8.2 $116.55
1/15/2025911,400 shares $100.51 million +1.3%N/A7.4 $110.28
12/31/2024900,100 shares $96.45 million +10.7%N/A7.5 $107.15
12/15/2024812,800 shares $95.02 million +3.5%N/A6.9 $116.91
11/30/2024785,700 shares $95.44 million -5.5%N/A7.1 $121.47
11/15/2024831,500 shares $92.89 million -9.5%N/A7.5 $111.71
Ready to give options a try? Your first trade (Ticker included) -INSIDE (Ad)

Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel

10/31/2024918,600 shares $97.10 million -8.1%N/A8.5 $105.70
10/15/20241,000,000 shares $104.39 million +0.4%N/A9.5 $104.39
9/30/2024996,100 shares $99.70 million +1.9%N/A8.7 $100.09
9/15/2024977,400 shares $102.40 million -1.8%N/A7.9 $104.77
8/31/2024995,000 shares $105.27 million -6.1%N/A8.1 $105.80
8/15/20241,060,000 shares $109.32 million +10.3%N/A8.3 $103.13
7/31/2024960,700 shares $104.71 million -12.7%N/A6.9 $108.99
7/15/20241,100,000 shares $106.34 million +17.7%N/A7.9 $96.67
6/30/2024934,400 shares $78.73 million -0.2%N/A6.5 $84.26
6/15/2024936,600 shares $74.98 million +32.3%N/A6.6 $80.06
5/31/2024707,700 shares $60.19 million -17.6%N/A4.3 $85.05
5/15/2024858,700 shares $73.65 million +7.9%N/A4.6 $85.77
4/30/2024795,600 shares $55.60 million -3.8%N/A4.3 $69.89
4/15/2024826,600 shares $65.94 million +23.0%5.0%4.9 $79.77
3/31/2024672,100 shares $49.13 million -23.3%4.1%4.1 $73.10
3/15/2024876,300 shares $62.30 million +14.9%5.3%5.8 $71.09
2/29/2024762,600 shares $60.51 million -15.0%4.6%5.3 $79.35
2/15/2024896,600 shares $66.93 million -3.6%5.5%7.3 $74.65
1/31/2024929,800 shares $67.97 million +1.0%5.7%8.1 $73.10
1/15/2024920,700 shares $66.84 million +2.2%6.9%8.2 $72.60
12/31/2023900,800 shares $64.34 million +0.8%5.5%8.2 $71.42
12/15/2023893,600 shares $60.18 million -1.7%5.5%8.1 $67.35
11/30/2023909,100 shares $53.01 million -2.3%5.5%8.8 $58.31
11/15/2023930,200 shares $52.54 million +6.1%5.7%9.2 $56.48
10/31/2023876,400 shares $45.83 million +3.8%5.4%8.8 $52.29
10/15/2023844,700 shares $46.45 million +2.5%5.2%8.8 $54.99
9/30/2023824,100 shares $49.38 million -0.1%5.1%8.4 $59.92
9/15/2023825,000 shares $51.13 million -6.2%5.1%8.8 $61.98
8/31/2023879,200 shares $57.82 million +4.6%5.4%9.1 $65.77
8/15/2023840,500 shares $56.81 million +4.3%5.2%8.6 $67.59
7/31/2023805,800 shares $53.93 million -3.4%5.0%8.2 $66.93
7/15/2023834,300 shares $56.61 million -1.4%5.1%8.4 $67.85
6/30/2023846,200 shares $61.01 million +4.0%5.2%8.6 $72.10
6/15/2023814,000 shares $64.30 million -1.6%5.0%7.8 $78.99
5/31/2023827,100 shares $57.96 million +1.3%5.1%7.9 $70.08
5/15/2023816,400 shares $63.34 million +0.7%5.0%7.2 $77.59
4/30/2023811,100 shares $61.93 million +5.1%5.1%7 $76.35
4/15/2023771,800 shares $57.38 million -1.0%4.8%6.6 $74.34
3/31/2023779,200 shares $57.32 million -13.5%4.9%6.5 $73.56
3/15/2023900,500 shares $64.48 million +7.5%5.6%7.1 $71.61
2/28/2023838,100 shares $60.46 million +2.5%5.2%5.1 $72.14
2/15/2023817,900 shares $59.69 million +1.5%5.1%4.8 $72.98
1/31/2023806,000 shares $56.18 million +0.1%5.1%4.6 $69.70
1/15/2023805,000 shares $57.38 million +1.5%5.1%4.1 $71.28
12/30/2022792,800 shares $52.96 million -8.4%5.0%4.1 $66.80
12/15/2022865,800 shares $53.81 million +13.0%5.5%4.4 $62.15
11/30/2022766,100 shares $55.85 million -2.3%4.8%4.6 $72.90
11/15/2022784,100 shares $61.99 million +6.6%4.9%5 $79.06
10/31/2022735,400 shares $64.46 million -0.3%4.6%5 $87.65
10/15/2022737,800 shares $66.03 million -6.7%4.6%6 $89.49
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
9/30/2022790,600 shares $68.08 million -5.1%5.0%6.6 $86.11
9/15/2022833,000 shares $75.08 million +3.1%5.2%7 $90.13
8/31/2022808,200 shares $74.67 million -3.7%5.1%6.6 $92.39
8/15/2022839,000 shares $90.03 million -3.2%5.3%6.8 $107.31
7/31/2022866,700 shares $79.76 million -0.8%5.4%6.5 $92.03
7/15/2022873,600 shares $82.58 million -3.6%5.4%6 $94.53
6/30/2022905,800 shares $80.82 million -0.2%5.6%6 $89.22
6/15/2022907,900 shares $71.80 million -0.6%N/A5.7 $79.08
5/31/2022913,400 shares $81.21 million -10.5%5.7%6.2 $88.91
5/15/20221,020,000 shares $87.68 million -8.9%6.4%6.2 $85.96
4/30/20221,120,000 shares $104.00 million No Change7.0%6.8 $92.86
4/15/20221,120,000 shares $117.89 million -8.9%7.0%6.8 $105.26
3/31/20221,230,000 shares $138.36 million +2.5%7.7%7.2 $112.49
3/15/20221,200,000 shares $125.44 million -2.4%7.5%7.5 $104.53
2/28/20221,230,000 shares $124.50 million No Change7.7%7.7 $101.22
2/15/20221,230,000 shares $152.13 million -10.2%7.8%8.1 $123.68
1/31/20221,370,000 shares $170.74 million -11.0%8.6%9.7 $124.63
1/15/20221,540,000 shares $192.36 million -4.4%9.7%11.3 $124.91
12/31/20211,610,000 shares $248.68 million -4.2%10.1%13.4 $154.46
12/15/20211,680,000 shares $247.80 million +5.0%10.6%13.9 $147.50
11/30/20211,600,000 shares $259.07 million +0.6%10.1%13.5 $161.92
11/15/20211,590,000 shares $260.93 million -4.2%10.0%8 $164.11
10/29/20211,660,000 shares $242.26 million No Change10.5%8 $145.94
10/15/20211,660,000 shares $216.23 million -4.1%10.5%7.9 $130.26
9/30/20211,730,000 shares $241.02 million -2.8%10.9%8 $139.32
9/15/20211,780,000 shares $241.83 million +10.6%11.2%7.8 $135.86
8/31/20211,610,000 shares $213.00 million -0.6%10.2%7 $132.30
8/13/20211,620,000 shares $173.05 million -1.8%10.2%10.1 $106.82
7/30/20211,650,000 shares $187.29 million -6.3%10.4%11 $113.51

LGND Short Interest - Frequently Asked Questions

Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 2,121,617 shares of LGND short. 11.38% of Ligand Pharmaceuticals' shares are currently sold short. Learn More on Ligand Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 2.6. Learn More on Ligand Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.38% of Ligand Pharmaceuticals' floating shares are currently sold short.

Ligand Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 2,121,617 shares, an increase of 25.6% from the previous total of 1,689,714 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

11.38% of Ligand Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Ligand Pharmaceuticals: ADMA Biologics Inc (10.88%), ANI Pharmaceuticals, Inc. (16.47%), Incyte Corporation (6.32%), United Therapeutics Corporation (5.46%), Neurocrine Biosciences, Inc. (5.77%), Exelixis, Inc. (11.66%), Madrigal Pharmaceuticals, Inc. (18.56%), BioMarin Pharmaceutical Inc. (7.26%), Halozyme Therapeutics, Inc. (11.44%), Ionis Pharmaceuticals, Inc. (10.74%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($82.01 billion), Invesco QQQ ($47.15 billion), iShares Russell 2000 ETF ($24.07 billion), Nebius Group N.V. ($16.85 billion), Western Digital Corporation ($14.29 billion), SPDR S&P Biotech ETF ($11.89 billion), VanEck Semiconductor ETF ($11.29 billion), KLA Corporation ($10.37 billion), iShares 20+ Year Treasury Bond ETF ($8.78 billion), and Lumentum Holdings Inc. ($8.29 billion). View all of the most shorted stocks.

Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading up $7.54 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is June, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like LGND:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:LGND) was last updated on 7/10/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel